(Q45161674)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15562367%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

title

Alendronate reduces bone resorption in HIV-associated osteopenia/osteoporosis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15562367%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

0 references

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15562367%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

Stefano Campostrini

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15562367%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

author name string

Orlando G

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15562367%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

Madeddu G

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15562367%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

Vescini F

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15562367%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

Ventura P

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15562367%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

Mura MS

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15562367%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

Parise N

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15562367%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

Caudarella R

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15562367%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

Esposito R

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15562367%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

publication date

1 September 2004

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15562367%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15562367%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

volume

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15562367%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15562367%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

page(s)

269-277

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15562367%20AND%20SRC:MED&resulttype=core&format=json

Serum type I collagen breakdown product (serum CTX) predicts hip fracture risk in elderly women: the EPIDOS study.

5 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1310%2FMD8V-5DLG-EN3T-BRHX

Osteoporosis prevention, diagnosis, and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FMD8V-5DLG-EN3T-BRHX

Alterations in bone turnover in HIV-positive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FMD8V-5DLG-EN3T-BRHX

Bone remodelling in human immunodeficiency virus-1-infected patients. A histomorphometric study

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FMD8V-5DLG-EN3T-BRHX

Bone mineral density in patients with human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FMD8V-5DLG-EN3T-BRHX

Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FMD8V-5DLG-EN3T-BRHX

Osteopenia in patients infected by the human immunodeficiency virus. A case control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FMD8V-5DLG-EN3T-BRHX

Changes in calciotropic hormones and biochemical markers of bone metabolism in patients with human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FMD8V-5DLG-EN3T-BRHX

Osteopenia in HIV-infected men: association with asymptomatic lactic acidemia and lower weight pre-antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FMD8V-5DLG-EN3T-BRHX

Pathological fractures in AIDS patients with osteopenia and osteoporosis induced by antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FMD8V-5DLG-EN3T-BRHX

Symptomatic osteoporosis in two young HIV-positive African women

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FMD8V-5DLG-EN3T-BRHX

Bone mass in HIV-infected patients: focus on the role of therapy and sex.

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FMD8V-5DLG-EN3T-BRHX

Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FMD8V-5DLG-EN3T-BRHX

Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FMD8V-5DLG-EN3T-BRHX

Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FMD8V-5DLG-EN3T-BRHX

Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FMD8V-5DLG-EN3T-BRHX

Alendronate for the Treatment of Osteoporosis in Men

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FMD8V-5DLG-EN3T-BRHX

Alendronate treatment for osteoporosis in patients infected with human immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FMD8V-5DLG-EN3T-BRHX

Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. WHO Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FMD8V-5DLG-EN3T-BRHX

Comparison of semiquantitative visual and quantitative morphometric assessment of prevalent and incident vertebral fractures in osteoporosis The Study of Osteoporotic Fractures Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FMD8V-5DLG-EN3T-BRHX

The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FMD8V-5DLG-EN3T-BRHX

Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FMD8V-5DLG-EN3T-BRHX

The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FMD8V-5DLG-EN3T-BRHX

A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FMD8V-5DLG-EN3T-BRHX

Alendronate does not block the anabolic effect of PTH in postmenopausal osteoporotic women

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FMD8V-5DLG-EN3T-BRHX

The Effects of Parathyroid Hormone, Alendronate, or Both in Men with Osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FMD8V-5DLG-EN3T-BRHX

A randomised, open-label comparison of three highly active antiretroviral therapy regimens including two nucleoside analogues and indinavir for previously untreated HIV-1 infection: the OzCombo1 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FMD8V-5DLG-EN3T-BRHX

10.1310/MD8V-5DLG-EN3T-BRHX

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15562367%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

1 reference